Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Zepharma on Track to Achieve Initial Business Targets
March 21, 2005
- Kanebo Aiming to Become Leader in Kampo Medicines
March 21, 2005
- Kobashou Aims to Build Nationwide Network by FY2007
March 21, 2005
- Marketing of Zione Inj to Focus on Specialists in 1st 2 Years: MPC
March 21, 2005
- OTC NEWS IN BRIEF
March 21, 2005
- BUSINESS NEWS IN BRIEF
March 21, 2005
- MEDICAL DEVICE NEWS IN BRIEF
March 21, 2005
- WEBSITE NEWS
March 21, 2005
- Annual Business Result
March 21, 2005
- Annual Business Results
March 21, 2005
- Sales of Ethical Drugs Rose 2.1% to \7.2 Tril. in 2004: IMS Japan
March 21, 2005
- Semiannual Business Results
March 21, 2005
- Alesion Dry Syrup, Enbrel, Zione to Be Added to NHI List on March 18
March 21, 2005
- Gov't-managed Health Insurance Benefits Down 7th Year in a Row in FY2003
March 21, 2005
- REGULATORY NEWS IN BRIEF
March 21, 2005
- PMDA Suspends Receipt of Applications for Clinical Trial Consultation
March 14, 2005
- TOPICS 2 articrels
March 14, 2005
- 3-Year Plan on Clinical Trials Enters Last Year
March 14, 2005
- BULLETIN
March 14, 2005
- SJP SEMINAR
March 14, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…